Biostem Technologies New

Good afternoon and welcome everyone to the BioSTEM Technologies second quarter 2026 earnings call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. At this time, I'd like to turn the conference over to Tripp Taylor, Investor Relations. Please go ahead.

Good afternoon, everyone, and thank you for joining our conference call to discuss BioSTEM's second quarter 2026 financial results and corporate highlights. Leading the call today will be Jason Matuszewski, the company's chairman and chief executive officer, Brandon Poe, the company's chief financial officer, and Barry Hassett, the company's chief commercial officer. Before we begin, I'd like to remind everyone that our remarks may contain forward-looking statements based on management's current expectations. These risks and uncertainties are more fully described in our press release issued today and in our filings with the US Securities and Exchange Commission. Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. Finally, this call also includes reference to non-GAAP financial measures. A reconciliation to comparable GAAP measures and related information can be found in our earnings press release posted on the investor relations section of BioSTEM's website. With that, I would now like to turn the call over to Jason Matuszewski.

Thank you, Tripp, and good afternoon, everyone. The second quarter was BioSTEM's first full quarter operating as a predominantly hospital-focused business. During the quarter, we increased hospital revenue sequentially to $6.7 million, completed the implementation of BioStem's own customer relationship management system, and continued building the commercial organization needed to support our growth strategy. After quarter end, we also completed our uplisting to the NASDAQ capital market, and our common stock began trading on NASDAQ on August 7th. I want to congratulate our team and thank our shareholders, employees, and business partners whose hard work helped us reach this important milestone. The NASDAQ uplisting broadens BioSIM's visibility, expands our access to the capital markets, and supports our ability to attract and retain talent. is an important corporate achievement and we are pleased to be trading on a national exchange that will enable us to maximize the value of the company through our fundamental business execution. We remain focused on four priorities designed to maximize value. First, completing and optimizing the integration of our product lines, internal systems, and commercial organization. Second, driving adoption and utilization across the hospital channel. Third, advancing our first 510K product and the broader product roadmap. And fourth, preparing for the manufacturing transfer of the Neox and Clarex product lines. We have made progress on each of these priorities during the quarter. Beginning with integration, our core commercial infrastructure is now in place and operating in line with our expectations. Until the beginning of August, BioTissue provided sales logistics, operational support, invoicing, and collections under a transition services agreement. That agreement provided business continuity while we built our internal systems and capabilities. We have now transitioned those functions in-house and launched the first phase of our new customer relationship management platform, integrated with our enterprise resource planning system. This automates and connects order processing, invoicing, and collections across our organization. These capabilities give us better visibility into account activity, ordering patterns, product utilization, and sales performance. They also improve our ability to target new accounts and support the organization as it scales. In parallel, we continue to integrating and expanding the commercial team. During the quarter, we introduced our bioretained dry products to the hospital sales organization, giving the team an additional product line to offer across its customer base. As our systems, order processing, and logistics become more integrated and automated, we expect the organization to become increasingly productive. To discuss our commercial efforts and product roadmap in greater detail, I will turn the call over to Barry Hassett, our Chief Commercial Officer.